Servier reported that sevasemten—acquired from Edgewise Therapeutics as part of a roughly $1.5 billion deal—missed statistical significance in a pivotal cohort of Becker muscular dystrophy, according to MedCity News. The drug had met a goal in a prior phase 2 study, but the new pivotal results did not confirm a benefit in the targeted population. Servier said it is conducting a deeper analysis of the GRAND CANYON-style dataset and relevant prior findings. The setback is a direct pressure point for patients with Becker muscular dystrophy, where there are currently no approved disease-modifying therapies.